Printer Friendly

ACCORD questions intensive glucose control.

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

A mean of 3.7 years of intensive glucose-lowering therapy reduced the risk of nonfatal myocardial infarction in patients with advanced type 2 diabetes and a high risk of cardiovascular disease, but increased the risk of death, according to 5-year outcomes from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Thus, a therapeutic approach that targets glycated hemoglobin levels below 6% cannot be recommend in this population, Dr. Hertzel C. Gerstein of McMaster University, Hamilton, Ont., and colleagues from the ACCORD Study Group reported.

ACCORD participants were 10,108 type 2 diabetes patients with cardiovascular disease who were randomly assigned to receive intensive glucose-lowering therapy to a target hemoglobin Ale below 6.0% or to standard therapy with a target [HbA.sub.1c] of 7.0%-7.9%.

The intensive therapy was terminated after a mean of 3.5 years because of higher mortality in the intensive-treatment group, and patients from that group began receiving standard therapy.

All participants were followed until the planned end of the trial; the current Findings reflect an additional 0.2 months of intensive therapy not previously reported, and up to 17 months of additional follow-up.

Prior to the transition, the incidence of the primary outcome (a composite of nonfatal MI, nonfatal stroke, or death from cardiovascular causes) was 2.0% per year in the intensive-therapy group, and 2.2% per year in the standard-therapy group (hazard ratio 0.90). The difference between the groups remained nonsignificant throughout the entire period of observation.

[ILLUSTRATION OMITTED]

Although the intensive therapy did lower the rate of nonfatal MI (1.08% vs. 1.35%, HR 0.79), it was also as sociated with a nonsignificant increased rate of death from cardiovascular causes (0.71% vs. 0.55%, HR 1.27).

"These divergent effects were retained at the end of the study, with a rate of nonfatal myocardial infarction in the intensive-therapy groups that was lower than in the standard-therapy group (1.18 vs. 1.42; hazard ratio 0.82) ... and a rate of death from cardiovascular causes that was higher (0.74 vs. 0.57; hazard ratio 1.29)," they found (N. Engl. J. Med. 2011;364:818-28).

At the time of transition, the death rate from any cause was a significant 21% higher in the intensive-therapy group (1.42 vs. 1.16), and it remained higher--by 19%-at the end of the study (1.53 vs. 1.27).

The findings indicate that 3.7 years of intensive therapy to target normal [HbA.sub.1c] in a high-risk population does not result in a significantly lower number of major cardiovascular events after 5 years, compared with therapy that targets "levels that are more typically achieved in person in the United States and Canada (i.e., 7 to 7.9%)," and indeed, the intensive approach was associated with more deaths, they said.

Reasons for the higher mortality in the intensive-therapy group prior to the transition to standard therapy are unclear, although findings from ACCORD and other studies rule out hypoglycemia and the degree of reduction in glycated hemoglobin levels as a cause, the investigators noted.

"'Further analysis should explore possible explanations, such as the role of various drugs, drug combinations, or drug interactions; weight gain; the relatively short intervention period (3.7 years); and the observed interaction between the blood pressure and glycemia trials with respect to mortality," they said.
COPYRIGHT 2011 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:METABOLIC DISORDERS
Author:Worcester, Sharon
Publication:Family Practice News
Date:Mar 15, 2011
Words:570
Previous Article:Diabetic moms' breastfed kids may stay lean.
Next Article:Insulin receptor genetic variants linked to type 2 diabetes.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters